Ocedurenone is under clinical development by KBP Biosciences and currently in Phase III for Chronic Kidney Disease (Chronic Renal Failure). According to GlobalData, Phase III drugs for Chronic Kidney Disease (Chronic Renal Failure) have a 62% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Ocedurenone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ocedurenone (KBP-5074) is under development for the treatment of uncontrolled hypertension, advanced chronic kidney disease, heart failure and moderate hepatic impairment. It is a small molecule administered orally in the form of capsule and tablet. KBP-5074 is a new chemical entity (NCE) which acts by targeting mineralocorticoid receptor (MR).
KBP Biosciences overview
KBP Biosciences is a biopharmaceutical company that discovers, develops and commercializes small molecule drugs to treat cardiorenal and infectious diseases. The company’s lead product candidate KBP-5074, a non-steroidal mineralocorticoid receptor antagonist (MRA) is used for the treatment of uncontrolled hypertension in patients with chronic kidney diseases. KBP Biosciences is also investigating KBP-7072, a tetracycline formulation targeting multi drug resistant bacteria infections; KPB-7026 against eosinophilic asthma; KBP-8017, a multi kinase inhibitor to treat fibrosis caused due to radiotherapy; and KBP-7909 drug targeting gram negative bacterial infections. Its proprietary discovery platform helps in estimating pharmacokinetics/pharmacodynamics (PK/PD) and toxicology across various drug candidates. The company has operations in the US. KBP BioSciences is headquartered in Shanghai, China.
For a complete picture of Ocedurenone’s drug-specific PTSR and LoA scores, buy the report here.